fluconazole has been researched along with minocycline in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Higuchi, B; Hirano, S; Inoue, M; Ishihara, T; Kawa, K; Kondo, O; Kouroki, M; Koyama, M; Sakata, A; Sakata, N; Sawada, A; Takeshita, Y; Yasui, M; Yoshioka, A | 1 |
| Cao, L; Chen, X; Chen, Z; Liu, P; Shi, W; Sun, S | 1 |
| Gao, Y; Li, H; Liu, P; Liu, W; Sun, S; Zhang, C | 1 |
| Chen, M; Shi, H; Sun, Y; Tan, L; Wang, Z; Yao, Z | 1 |
| Barbosa, AD; Cabral, VPF; Cavalcanti, BC; da Silva, AR; da Silva, CR; da Silva, LJ; de Andrade Neto, JB; de Andrade, CR; de Moraes, MO; Gomes, AOCV; Moreira, LEA; Nobre Júnior, HV; Rodrigues, DS; Sá, LGDAV; Silveira, MJCB; Soares, GC | 1 |
1 review(s) available for fluconazole and minocycline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fluconazole and minocycline
| Article | Year |
|---|---|
[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation].
Topics: Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Echinocandins; Female; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lipopeptides; Male; Meropenem; Micafungin; Minocycline; Mycoses; Neutropenia; Opportunistic Infections; Organophosphates; Prodrugs; Thienamycins | 2009 |
10 other study(ies) available for fluconazole and minocycline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: an in vitro interaction of antifungal and antibacterial agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Drug Synergism; Fluconazole; Microbial Sensitivity Tests; Minocycline | 2010 |
In vitro interactions between fluconazole and minocycline against mixed cultures of Candida albicans and Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Antifungal Agents; Biofilms; Calcium; Candida albicans; Candidiasis; Coinfection; Drug Interactions; Drug Synergism; Fluconazole; Humans; Microbial Sensitivity Tests; Minocycline; Staphylococcal Infections; Staphylococcus aureus | 2015 |
In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
Topics: Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; HIV Infections; Humans; Microbial Sensitivity Tests; Minocycline | 2022 |
Analysis of possible pathways on the mechanism of action of minocycline and doxycycline against strains of
Topics: Anti-Bacterial Agents; Antifungal Agents; Candida; Doxycycline; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Minocycline | 2023 |